Preclinical investigation of the safety of eplir

A. S. Saratikov, N. S. Livshits, F. I. Burchenkova, N. G. Kadychagova, T. P. Novozheeva, R. R. Akhmedzhanov, T. V. Perevozchikova, L. V. Bashirova

Research output: Contribution to journalArticle

Abstract

The preclinical toxicological evaluation of eplir, a new hepatoprotective drug, has been performed. It was established that, in terms of the acute toxicity parameters, eplir is a low-toxicity substance. A six-month peroral administration of the drug in a dose of 30, 150, and 300 mg/kg in rats and 100 mg/kg in dogs did not cause any substantial functional and structural disorders in the organs and systems of the experimental animals. Eplir does not possess mutagenic, carcinogenic, allergenic, and immunotoxic properties and does not affect the reproductive function.

Original languageEnglish
Pages (from-to)64-66
Number of pages3
JournalPharmaceutical Chemistry Journal
Volume39
Issue number2
DOIs
Publication statusPublished - 1 Feb 2005

Fingerprint

Safety
Pharmaceutical Preparations
Toxicology
Dogs
eplir

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Saratikov, A. S., Livshits, N. S., Burchenkova, F. I., Kadychagova, N. G., Novozheeva, T. P., Akhmedzhanov, R. R., ... Bashirova, L. V. (2005). Preclinical investigation of the safety of eplir. Pharmaceutical Chemistry Journal, 39(2), 64-66. https://doi.org/10.1007/s11094-005-0082-3

Preclinical investigation of the safety of eplir. / Saratikov, A. S.; Livshits, N. S.; Burchenkova, F. I.; Kadychagova, N. G.; Novozheeva, T. P.; Akhmedzhanov, R. R.; Perevozchikova, T. V.; Bashirova, L. V.

In: Pharmaceutical Chemistry Journal, Vol. 39, No. 2, 01.02.2005, p. 64-66.

Research output: Contribution to journalArticle

Saratikov, AS, Livshits, NS, Burchenkova, FI, Kadychagova, NG, Novozheeva, TP, Akhmedzhanov, RR, Perevozchikova, TV & Bashirova, LV 2005, 'Preclinical investigation of the safety of eplir', Pharmaceutical Chemistry Journal, vol. 39, no. 2, pp. 64-66. https://doi.org/10.1007/s11094-005-0082-3
Saratikov AS, Livshits NS, Burchenkova FI, Kadychagova NG, Novozheeva TP, Akhmedzhanov RR et al. Preclinical investigation of the safety of eplir. Pharmaceutical Chemistry Journal. 2005 Feb 1;39(2):64-66. https://doi.org/10.1007/s11094-005-0082-3
Saratikov, A. S. ; Livshits, N. S. ; Burchenkova, F. I. ; Kadychagova, N. G. ; Novozheeva, T. P. ; Akhmedzhanov, R. R. ; Perevozchikova, T. V. ; Bashirova, L. V. / Preclinical investigation of the safety of eplir. In: Pharmaceutical Chemistry Journal. 2005 ; Vol. 39, No. 2. pp. 64-66.
@article{3087cee4bf564ebbbb4b502f317bf5cc,
title = "Preclinical investigation of the safety of eplir",
abstract = "The preclinical toxicological evaluation of eplir, a new hepatoprotective drug, has been performed. It was established that, in terms of the acute toxicity parameters, eplir is a low-toxicity substance. A six-month peroral administration of the drug in a dose of 30, 150, and 300 mg/kg in rats and 100 mg/kg in dogs did not cause any substantial functional and structural disorders in the organs and systems of the experimental animals. Eplir does not possess mutagenic, carcinogenic, allergenic, and immunotoxic properties and does not affect the reproductive function.",
author = "Saratikov, {A. S.} and Livshits, {N. S.} and Burchenkova, {F. I.} and Kadychagova, {N. G.} and Novozheeva, {T. P.} and Akhmedzhanov, {R. R.} and Perevozchikova, {T. V.} and Bashirova, {L. V.}",
year = "2005",
month = "2",
day = "1",
doi = "10.1007/s11094-005-0082-3",
language = "English",
volume = "39",
pages = "64--66",
journal = "Pharmaceutical Chemistry Journal",
issn = "0091-150X",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Preclinical investigation of the safety of eplir

AU - Saratikov, A. S.

AU - Livshits, N. S.

AU - Burchenkova, F. I.

AU - Kadychagova, N. G.

AU - Novozheeva, T. P.

AU - Akhmedzhanov, R. R.

AU - Perevozchikova, T. V.

AU - Bashirova, L. V.

PY - 2005/2/1

Y1 - 2005/2/1

N2 - The preclinical toxicological evaluation of eplir, a new hepatoprotective drug, has been performed. It was established that, in terms of the acute toxicity parameters, eplir is a low-toxicity substance. A six-month peroral administration of the drug in a dose of 30, 150, and 300 mg/kg in rats and 100 mg/kg in dogs did not cause any substantial functional and structural disorders in the organs and systems of the experimental animals. Eplir does not possess mutagenic, carcinogenic, allergenic, and immunotoxic properties and does not affect the reproductive function.

AB - The preclinical toxicological evaluation of eplir, a new hepatoprotective drug, has been performed. It was established that, in terms of the acute toxicity parameters, eplir is a low-toxicity substance. A six-month peroral administration of the drug in a dose of 30, 150, and 300 mg/kg in rats and 100 mg/kg in dogs did not cause any substantial functional and structural disorders in the organs and systems of the experimental animals. Eplir does not possess mutagenic, carcinogenic, allergenic, and immunotoxic properties and does not affect the reproductive function.

UR - http://www.scopus.com/inward/record.url?scp=21644461203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21644461203&partnerID=8YFLogxK

U2 - 10.1007/s11094-005-0082-3

DO - 10.1007/s11094-005-0082-3

M3 - Article

AN - SCOPUS:21644461203

VL - 39

SP - 64

EP - 66

JO - Pharmaceutical Chemistry Journal

JF - Pharmaceutical Chemistry Journal

SN - 0091-150X

IS - 2

ER -